Skip to main content
ORASURE TECHNOLOGIES INC logo

ORASURE TECHNOLOGIES INC — Investor Relations & Filings

Ticker · OSUR ISIN · US68554V1089 LEI · 529900GNNJPNM4XHXQ77 US Manufacturing
Filings indexed 1,018 across all filing types
Latest filing 2021-11-04 Interim / Quarterly Rep…
Country US United States of America
Listing US OSUR

About ORASURE TECHNOLOGIES INC

https://www.orasure.com/

OraSure Technologies, Inc. develops, manufactures, and distributes diagnostic products and sample collection tools. The company specializes in non-invasive technologies, particularly oral fluid-based solutions, to decentralize diagnostics and improve healthcare access. Its portfolio includes point-of-care and over-the-counter rapid tests for infectious diseases such as HIV and COVID-19. A notable achievement is the development of the first over-the-counter at-home HIV test. Through its subsidiaries, OraSure also provides sample management solutions for the collection of biological samples used in genomic, metabolomic, and microbiome research, serving healthcare providers, researchers, and consumers.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2021
2021-11-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates. The text specifically mentions the announcement of quarterly financial results for the quarter ended September 30, 2021, and includes a press release, prepared remarks for a conference call, and a slide presentation. The document does not contain the full financial statements or detailed financial analysis itself but rather announces and attaches exhibits related to the earnings release and conference call. This fits the definition of an Earnings Release (ER) since it is the initial announcement of quarterly financial results with key highlights. The presence of a press release and conference call materials further supports this classification. The document length (5826 characters) and content confirm it is not a full interim report (IR) or annual report (10-K). Therefore, the best classification is Earnings Release (ER).
2021-11-03 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. It announces a material definitive agreement for $109 million in funding from the U.S. Department of Defense to expand manufacturing capacity. The document includes details about the agreement, its terms, and references a press release attached as an exhibit. There are no financial statements or detailed financial data presented, and the document is primarily an announcement of a capital funding agreement. This fits the category of Capital/Financing Update (CAP). The document length is over 6000 characters, indicating it is not a brief announcement but a substantive filing about financing activity.
2021-10-04 English
PRIMARY DOCUMENT
Director's Dealing
2021-10-01 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes a funding agreement with BARDA for COVID-19 test development, and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is a regulatory announcement of a material event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-09-23 English
PRIMARY DOCUMENT
Director's Dealing
2021-09-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.